Clear Search

Books+ Search Results

Location: Is
Is Is Not
HathiTrust Digital Library
Subject with Hierarchy: Is
Is Is Not
Drug development

Advanced Search

Basic Search
Help
Add a row
Reset

Limit results by

Results are already all online
Viewing Online Items
1.
PDUFA V : medical innovation, jobs, and patients : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, first session, July 7, 2011
Author
United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health
Published
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2012.
Online
Online book
Location
HathiTrust Digital Library >> Online Resource
Format
Books / Online
2.
Food and Drug Administration's review process for products to treat rare diseases and neglected tropical diseases : hearing before a subcommittee of the Committee on Appropriations, United States Senate, One Hundred Eleventh Congress, second session, special hearing, June 23, 2010, Washington, D.C
Author
United States. Congress. Senate. Committee on Appropriations. Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies
Published
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2011
Online
Online book
Location
HathiTrust Digital Library >> Online Resource
Format
Books / Online
3.
Biologics and biosimilars : balancing incentives for innovation : hearing before the Subcommittee on Courts and Competition Policy of the Committee on the Judiciary, House of Representatives, One Hundred Eleventh Congress, first session, July 14, 2009
Author
United States. Congress. House. Committee on the Judiciary. Subcommittee on Courts and Competition Policy
Published
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2010.
Online
Online book
Online book
Location
HathiTrust Digital Library >> Online Resource
Format
Books / Online
4.
Follow-on biologics : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007
Author
United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions
Published
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2008.
Online
4.L 11/4:S.HRG.110-375
Location
HathiTrust Digital Library >> Online Resource
Format
Books / Online
5.
Food and Drug Administration's Critical Path Initiative : hearing before a subcommittee of the Committee on Appropriations, United States Senate, One Hundred Tenth Congress, first session, special hearing, June 1, 2007, Salt Lake City, Utah
Author
United States. Congress. Senate. Committee on Appropriations. Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies
Published
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2008.
Online
4.AP 6/2:S.HRG.110-293
Location
HathiTrust Digital Library >> Online Resource
Format
Books / Online
6.
Norplant and contraceptive pricing : conflict of interest, protection of public ownership in drug development deals between tax-exempt, federally supported labs and the pharmaceutical industry : hearing before the Subcommittee on Regulation, Business Opportunities, and Technology of the Committee on Small Business, House of Representatives, One Hundred Third Congress, first session
Author
United States. Congress. House. Committee on Small Business. Subcommittee on Regulation, Business Opportunities, and Technology
Published
Washington : U.S. G.P.O. : For sale by the U.S. G.P.O., Supt. of Docs., Congressional Sales Office, 1994-
Online
4.SM 1:103-59
pt.3
Location
HathiTrust Digital Library >> Online Resource
Format
Books / Online
7.
Conflict of interest, protection of public ownership, in drug development deals between tax-exempt, federally supported labs and the pharmaceutical industry : hearing before the Subcommittee on Regulation, Business Opportunities, and Technology of the Committee on Small Business, House of Representatives, One Hundred Third Congress, first session
Author
United States. Congress. House. Committee on Small Business. Subcommittee on Regulation, Business Opportunities, and Technology
Published
Washington : U.S. G.P.O. : For sale by the U.S. G.P.O., Supt. of Docs., Congressional Sales Office, 1993-
Online
103-25
103-5
4.SM 1:103-25
4.SM 1:103-5
Location
HathiTrust Digital Library >> Online Resource
Format
Books / Online
8.
Oversight of the drug development program of the National Cancer Institute, 1982 : hearing before the Subcommittee on Investigations and General Oversight of the Committee on Labor and Human Resources, United States Senate, Ninety-seventh Congress, second session on examination of effective alternatives toward correcting deficiencies in the use of experimental drugs on cancer patients, March 5, 1982
Author
United States. Congress. Senate. Committee on Labor and Human Resources. Subcommittee on Investigations and General Oversight
Published
Washington : U.S. G.P.O. : [For sale by the Supt. of Docs., U.S. G.P.O., Congressional Sales Office], 1982.
Online
Online book
Online book
Location
HathiTrust Digital Library >> Online Resource
Format
Books / Online